COMBI.ST
Combigene AB
Price:  
2.48 
SEK
Volume:  
27,685.00
Sweden | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

COMBI.ST WACC - Weighted Average Cost of Capital

The WACC of Combigene AB (COMBI.ST) is 5.9%.

The Cost of Equity of Combigene AB (COMBI.ST) is 6.15%.
The Cost of Debt of Combigene AB (COMBI.ST) is 7.00%.

Range Selected
Cost of equity 5.30% - 7.00% 6.15%
Tax rate 20.60% - 20.90% 20.75%
Cost of debt 7.00% - 7.00% 7.00%
WACC 5.4% - 6.3% 5.9%
WACC

COMBI.ST WACC calculation

Category Low High
Long-term bond rate 2.5% 3.0%
Equity market risk premium 5.1% 6.1%
Adjusted beta 0.35 0.41
Additional risk adjustments 1.0% 1.5%
Cost of equity 5.30% 7.00%
Tax rate 20.60% 20.90%
Debt/Equity ratio 1 1
Cost of debt 7.00% 7.00%
After-tax WACC 5.4% 6.3%
Selected WACC 5.9%

COMBI.ST's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for COMBI.ST:

cost_of_equity (6.15%) = risk_free_rate (2.75%) + equity_risk_premium (5.60%) * adjusted_beta (0.35) + risk_adjustments (1.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.